Throughout the quarter, INBS announced the completion of the in-clinic portion of its FDA 510 (k) clinical study plan. An initial review of the PK study data shows that fingerprint sweat aligns ...

The Phase 2 TRANQUILITY trial, which evaluates quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease, is ...